4582.T
SymBio Pharmaceuticals Limited
グロース · 医薬品 · 医薬品 · JP
JPY 61.00
−1.61%Year over year
Reported trailing growth
- Revenue
- -39.8%
- EBITDA
- —
- EBIT
- -32.4%
- EPS
- -10.7%
- Free cash flow
- —
- Operating cash flow
- —
Forward estimates
Based on analyst estimates
- Revenue
- +204.9%
- EBITDA
- —
- EPS
- +31.6%
Three-year CAGR
- Revenue
- -49.3%
- EBITDA
- —
- EBIT
- -14.6%
- Net income
- -24.6%
- EPS
- -11.9%
- Free cash flow
- —
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Mar 1, 2026